Acasti Pharma Inc

For the period ended Mar 31, 2024. Filed Jun 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Jun 21, 2024

GRCE$1.87+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	March 31, 2024	March 31, 2023
(Expressed in thousands except share data)	$	$
Assets
Current assets:
Cash and cash equivalents	23,005	27,875
Short-term investments	—	15
Receivables	722	802
Prepaid expenses	283	598
Total current assets	24,010	29,290
Operating lease right of use asset	—	463
Equipment, net	24	104
Intangible assets	41,128	41,128
Goodwill	8,138	8,138
Total assets	73,300	79,123
Liabilities and Shareholders’ equity
Current liabilities:
Trade and other payables	1,684	3,336
Operating lease liability	—	75
Total current liabilities	1,684	3,411
Derivative warrant liabilities	4,359	—
Operating lease liability	—	410
Deferred tax liability	5,514	7,347
Total liabilities	11,557	11,168
Commitments and contingencies (Note 13)
Shareholders’ equity:
Class A common shares, no par value per share; unlimited shares authorized; 9,399,404 and 7,435,533 shares issued and outstanding as of March 31, 2024 and 2023,respectively	261,038	258,294
Class B, C, D and E common shares, no par value per share; unlimited shares authorized; none issued and outstanding	—	—
Additional paid-in capital	17,862	13,965
Accumulated other comprehensive loss	(6,038)	(6,038)
Accumulated deficit	(211,119)	(198,266)
Total shareholders' equity	61,743	67,955
Total liabilities and shareholders’ equity	73,300	79,123

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.